Bifogade filer
Senzime’s investor event: Focus on growth, new clinical guidelines and updated financial outlook
Kurs
-16,92%
Likviditet
2,13 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2025-11-07 | 08:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-27 | 08:30 | Kvartalsrapport 2025-Q2 |
| 2025-05-20 | N/A | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2025-05-19 | N/A | Årsstämma |
| 2025-04-22 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-17 | - | Bokslutskommuniké 2024 |
| 2024-11-06 | - | Kvartalsrapport 2024-Q3 |
| 2024-10-23 | - | Extra Bolagsstämma 2024 |
| 2024-08-26 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-17 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2024-05-16 | - | Årsstämma |
| 2024-05-07 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-15 | - | Bokslutskommuniké 2023 |
| 2023-11-28 | - | Extra Bolagsstämma 2023 |
| 2023-10-26 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-17 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2023-05-16 | - | Årsstämma |
| 2023-04-28 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-20 | - | Bokslutskommuniké 2022 |
| 2023-02-16 | - | Extra Bolagsstämma 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-15 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-19 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2022-05-18 | - | Årsstämma |
| 2022-05-05 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-12 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-27 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2021-05-11 | - | Årsstämma |
| 2021-05-06 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-05 | - | Extra Bolagsstämma 2021 |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-11-06 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-02 | - | Extra Bolagsstämma 2020 |
| 2020-05-15 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2020-05-14 | - | Årsstämma |
| 2020-05-08 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-11-08 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-08-21 | - | Extra Bolagsstämma 2019 |
| 2019-05-09 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2019-05-08 | - | Årsstämma |
| 2019-05-08 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-15 | - | Bokslutskommuniké 2018 |
| 2018-11-08 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-22 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-09 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2018-05-08 | - | Årsstämma |
| 2018-05-08 | - | Kvartalsrapport 2018-Q1 |
| 2018-03-05 | - | Extra Bolagsstämma 2018 |
| 2018-02-16 | - | Bokslutskommuniké 2017 |
| 2017-11-28 | - | Kvartalsrapport 2017-Q3 |
| 2017-09-15 | - | Extra Bolagsstämma 2017 |
| 2017-08-31 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-23 | - | Årsstämma |
| 2017-05-23 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-16 | - | Bokslutskommuniké 2016 |
| 2016-11-22 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-31 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-17 | - | Extra Bolagsstämma 2016 |
| 2016-04-28 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2016-04-27 | - | Årsstämma |
| 2016-04-27 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-18 | - | Bokslutskommuniké 2015 |
| 2015-11-24 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-26 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-20 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2015-05-19 | - | Årsstämma |
| 2015-05-19 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-25 | - | Bokslutskommuniké 2014 |
| 2014-11-27 | - | Kvartalsrapport 2014-Q3 |
| 2014-11-21 | - | Extra Bolagsstämma 2014 |
| 2014-08-21 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-15 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2014-05-14 | - | Årsstämma |
| 2014-05-14 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-24 | - | Bokslutskommuniké 2013 |
| 2013-11-27 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-20 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-16 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2013-05-15 | - | Årsstämma |
| 2013-05-15 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-28 | - | Bokslutskommuniké 2012 |
| 2013-01-08 | - | Extra Bolagsstämma 2013 |
| 2012-11-21 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-21 | - | Kvartalsrapport 2012-Q2 |
| 2012-05-24 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2012-05-23 | - | Årsstämma |
| 2012-05-23 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-22 | - | Bokslutskommuniké 2011 |
| 2011-11-23 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-23 | - | Kvartalsrapport 2011-Q2 |
| 2011-05-27 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2011-05-26 | - | Årsstämma |
| 2011-05-26 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-16 | - | Bokslutskommuniké 2010 |
| 2010-11-24 | - | Kvartalsrapport 2010-Q3 |
| 2010-05-28 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
| 2010-05-27 | - | Kvartalsrapport 2010-Q1 |
| 2009-11-25 | - | Kvartalsrapport 2009-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Uppsala, November 15, 2022. Senzime AB (publ) will give an update at today’s investor event on the strategy following the acquisition of Respiratory Motion (RMI), present the growth opportunities in the market given the new US and European clinical guidelines supporting Senzime’s solutions, and provide an updated financial outlook.
Highlights that Senzime will present at today’s digital investor event starting at 13:00 CET include:
- Senzime is on a mission to build a global leader within patient monitoring to eliminate anesthesia- and respiratory-related complications. There is a technology shift in the market supporting new innovative products.
- New clinical guidelines were recently approved in the US recommending Senzime’s type of technology for patient monitoring. Senzime is well-positioned to gain market share and continue to drive the technology shift in neuromuscular monitoring to reduce complications, improve patient health and save healthcare cost.
- The recent acquisition of RMI and its monitoring solution ExSpiron has strengthened the product portfolio and expanded the market opportunity significantly. Focus is to continue to roll-out the products in key markets.
- The strategic collaboration with US company Masimo creates further market opportunities, expands reach, and gives more patients access to Senzime’s monitoring solutions. The first joint solutions are expected to reach the market in the beginning of 2024.
Financial outlook: - Net sales estimated to reach 275-325 MSEK by 2025, and long-term EBITDA margin estimated to exceed 40 percent. Senzime shall reach a market share of at least 10 percent in its active market segments.
"Senzime is in an exciting position with an innovative product portfolio supported by new clinical guidelines. We are well-positioned to continue our journey to build a leading position within our segments, drive growth and long-term profitability”, says Pia Renaudin, CEO Senzime.
At today’s investor event, Pia Renaudin, CEO, will together with Kay Krüger (Business manager of ExSpiron products) and Sorin J. Brull (Professor, board member of Senzime AB and the innovator of TetraGraph) present company strategy, growth opportunities, new clinical guidelines, and long-term financial targets.
The presentations will be held in English, followed by a Q&A session. Attendees will be able to submit questions via the webcast.
Date and time
Tuesday November 15, 2022, at 13:00-15:00 CET.
Link:
The webcast can be followed live via the link: Investor event webcast
After the event, there will be a recording available at senzime.com.
For further information, please contact:
Pia Renaudin, CEO of Senzime AB
Phone: +46 (0) 70-813 34 17, email: pia.renaudin@senzime.com
About Senzime
Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.
Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.
This information is information that Senzime is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-11-15 10:00 CET.